Cyclooxygenases and the cardiovascular system.


Journal

Pharmacology & therapeutics
ISSN: 1879-016X
Titre abrégé: Pharmacol Ther
Pays: England
ID NLM: 7905840

Informations de publication

Date de publication:
01 2021
Historique:
received: 20 04 2020
accepted: 30 06 2020
pubmed: 9 7 2020
medline: 16 11 2021
entrez: 9 7 2020
Statut: ppublish

Résumé

Cyclooxygenase (COX)-1 and COX-2 are centrally important enzymes within the cardiovascular system with a range of diverse, sometimes opposing, functions. Through the production of thromboxane, COX in platelets is a pro-thrombotic enzyme. By contrast, through the production of prostacyclin, COX in endothelial cells is antithrombotic and in the kidney regulates renal function and blood pressure. Drug inhibition of COX within the cardiovascular system is important for both therapeutic intervention with low dose aspirin and for the manifestation of side effects caused by nonsteroidal anti-inflammatory drugs. This review focuses on the role that COX enzymes and drugs that act on COX pathways have within the cardiovascular system and provides an in-depth resource covering COX biology and pharmacology. The review goes on to consider the role of COX in both discrete cardiovascular locations and in associated organs that contribute to cardiovascular health. We discuss the importance of, and strategies to manipulate the thromboxane: prostacyclin balance. Finally within this review the authors discuss testable COX-2-hypotheses intended to stimulate debate and facilitate future research and therapeutic opportunities within the field.

Identifiants

pubmed: 32640277
pii: S0163-7258(20)30154-6
doi: 10.1016/j.pharmthera.2020.107624
pii:
doi:

Substances chimiques

Anti-Inflammatory Agents, Non-Steroidal 0
Cyclooxygenase Inhibitors 0
Prostaglandins 0
Thromboxanes 0
Cyclooxygenase 1 EC 1.14.99.1
Cyclooxygenase 2 EC 1.14.99.1
Prostaglandin-Endoperoxide Synthases EC 1.14.99.1
Aspirin R16CO5Y76E

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

107624

Subventions

Organisme : British Heart Foundation
ID : RG/18/4/33541
Pays : United Kingdom
Organisme : British Heart Foundation
ID : FS/19/6/34129
Pays : United Kingdom
Organisme : British Heart Foundation
ID : FS/16/1/31699
Pays : United Kingdom
Organisme : British Heart Foundation
ID : PG/15/47/31591
Pays : United Kingdom
Organisme : British Heart Foundation
ID : PG/15/79/31777
Pays : United Kingdom
Organisme : British Heart Foundation
ID : PG/17/40/33028
Pays : United Kingdom
Organisme : Wellcome Trust
Pays : United Kingdom

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest Within the past 5 years, JAM is a member of the scientific advisory board of Antibe Therapeutics Inc. and has received contributions including ‘in kind’ from Gesynta Pharma AB, Actelion and Merck Sharp & Dohme Limited. Other authors declare no conflicts of interest to declare.

Auteurs

Jane A Mitchell (JA)

Cardiothoracic Pharmacology, National Heart and Lung Institute, Imperial College London, SW7 2AZ, United Kingdom. Electronic address: j.a.mitchell@ic.ac.uk.

Nicholas S Kirkby (NS)

Cardiothoracic Pharmacology, National Heart and Lung Institute, Imperial College London, SW7 2AZ, United Kingdom. Electronic address: n.kirkby@imperial.ac.uk.

Blerina Ahmetaj-Shala (B)

Cardiothoracic Pharmacology, National Heart and Lung Institute, Imperial College London, SW7 2AZ, United Kingdom.

Paul C Armstrong (PC)

Blizard Institute, Barts and The London School of Medicine and Dentistry, The Blizard Building, 4 Newark Street, London E1 2AT, United Kingdom.

Marilena Crescente (M)

Blizard Institute, Barts and The London School of Medicine and Dentistry, The Blizard Building, 4 Newark Street, London E1 2AT, United Kingdom.

Plinio Ferreira (P)

Cardiothoracic Pharmacology, National Heart and Lung Institute, Imperial College London, SW7 2AZ, United Kingdom; Blizard Institute, Barts and The London School of Medicine and Dentistry, The Blizard Building, 4 Newark Street, London E1 2AT, United Kingdom.

Maria Elisa Lopes Pires (ME)

Cardiothoracic Pharmacology, National Heart and Lung Institute, Imperial College London, SW7 2AZ, United Kingdom; Blizard Institute, Barts and The London School of Medicine and Dentistry, The Blizard Building, 4 Newark Street, London E1 2AT, United Kingdom.

Ricky Vaja (R)

Cardiothoracic Pharmacology, National Heart and Lung Institute, Imperial College London, SW7 2AZ, United Kingdom; Blizard Institute, Barts and The London School of Medicine and Dentistry, The Blizard Building, 4 Newark Street, London E1 2AT, United Kingdom.

Timothy D Warner (TD)

Blizard Institute, Barts and The London School of Medicine and Dentistry, The Blizard Building, 4 Newark Street, London E1 2AT, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH